Literature DB >> 15073116

Endothelin-1-, endothelin-A-, and endothelin-B-receptor expression is correlated with vascular endothelial growth factor expression and angiogenesis in breast cancer.

Pia Wülfing1, Christian Kersting, Joke Tio, Rudolph-Josef Fischer, Christian Wülfing, Christopher Poremba, Raihanatou Diallo, Werner Böcker, Ludwig Kiesel.   

Abstract

PURPOSE: Endothelin-1 (ET-1) and its receptors (ET(A)R and ET(B)R), referred to as the endothelin (ET) axis, are overexpressed in breast carcinomas, and influence tumorigenesis and tumor progression by various mechanisms, including angiogenesis. The objective of the study was to clarify if expression of the ET axis participates in angiogenesis of breast carcinoma EXPERIMENTAL
DESIGN: We analyzed expression of ET-1, ET(A)R, ET(B)R, and vascular endothelial growth factor (VEGF) immunohistochemically in 600 tissue array specimens from 200 paraffin-embedded breast carcinomas performing tissue microarray technology. Microvessel density (MVD) was determined by counting microvessels (identified by factor VIII) in each core specimen.
RESULTS: Moderate or strong immunostaining was observed for ET-1 in 25.4%, for ET(A)R in 43.7%, and for ET(B)R in 22.2% of breast carcinomas. Of all cases, 44.7% showed significant expression of VEGF. MVD varied between different tumor specimens (range, 0-80; median, 17). We observed a statistically significant correlation between MVD and ET expression status with higher MVD in ET-positive tumors. Moreover, expression of VEGF was found more frequently in tumors with overexpression of the ET axis (each P < 0.001). Staining of VEGF was correlated positively with MVD
CONCLUSIONS: These results indicate that increased ET-1, ET(A)R, and ET(B)R expression is associated with increased VEGF expression and higher vascularity of breast carcinomas and, thus, could be involved in the regulation of angiogenesis in breast cancer. Our findings provide evidence that the expression pattern of the ET-axis and in particular of ET(A)R may have clinical relevance in future antiangiogenic targeted therapies for breast cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15073116     DOI: 10.1158/1078-0432.ccr-03-0115

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

1.  Expression of endothelin 1 and its angiogenic role in meningiomas.

Authors:  Laura Boldrini; Sabina Pistolesi; Silvia Gisfredi; Silvia Ursino; Greta Alì; Nicola Pieracci; Fulvio Basolo; Giuliano Parenti; Gabriella Fontanini
Journal:  Virchows Arch       Date:  2006-09-30       Impact factor: 4.064

Review 2.  A clinical-pathogenetic approach on associated anomalies and chromosomal defects supports novel candidate critical regions and genes for gastroschisis.

Authors:  Victor M Salinas-Torres; Rafael A Salinas-Torres; Ricardo M Cerda-Flores; Hugo L Gallardo-Blanco; Laura E Martínez-de-Villarreal
Journal:  Pediatr Surg Int       Date:  2018-08-09       Impact factor: 1.827

3.  Bosentan inhibits tumor vascularization and bone metastasis in an immunocompetent skin-fold chamber model of breast carcinoma cell metastasis.

Authors:  Didier Dréau; Amel Karaa; Cathy Culberson; Heather Wyan; Iain H McKillop; Mark G Clemens
Journal:  Clin Exp Metastasis       Date:  2006-07-07       Impact factor: 5.150

4.  Endothelin: Ominous Player in Breast Cancer.

Authors:  Anuradha Ratna; Salil K Das
Journal:  J Cancer Clin Trials       Date:  2015-10-12

Review 5.  Endothelin 1 in cancer: biological implications and therapeutic opportunities.

Authors:  Laura Rosanò; Francesca Spinella; Anna Bagnato
Journal:  Nat Rev Cancer       Date:  2013-07-25       Impact factor: 60.716

6.  Tumor lymphangiogenesis and metastasis to lymph nodes induced by cancer cell expression of podoplanin.

Authors:  Leah N Cueni; Ivan Hegyi; Jay W Shin; Andrea Albinger-Hegyi; Silke Gruber; Rainer Kunstfeld; Holger Moch; Michael Detmar
Journal:  Am J Pathol       Date:  2010-07-08       Impact factor: 4.307

7.  CXCL5 overexpression is associated with late stage gastric cancer.

Authors:  Jeong Youp Park; Kyung Hwa Park; Seungmin Bang; Myoung Hwan Kim; Ji-Eun Lee; Jingu Gang; Sang Seok Koh; Si Young Song
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-04       Impact factor: 4.553

8.  TrkBT1 induces liver metastasis of pancreatic cancer cells by sequestering Rho GDP dissociation inhibitor and promoting RhoA activation.

Authors:  Zhongkui Li; Zhe Chang; Lucia J Chiao; Ya'an Kang; Qianghua Xia; Cihui Zhu; Jason B Fleming; Douglas B Evans; Paul J Chiao
Journal:  Cancer Res       Date:  2009-09-22       Impact factor: 12.701

9.  Upregulation of C-X-C chemokine receptor type 1 expression is associated with late-stage gastric adenocarcinoma.

Authors:  Jun Pu Wang; Wan Ming Hu; Kuan Song Wang; Bai Hua Luo; Chang Wu; Zhi Hong Chen; Geng Qiu Luo; Yu Wu Liu; Qin Lai Liu; Jun Yu; Jing He Li; Ji Fang Wen
Journal:  Exp Ther Med       Date:  2012-05-07       Impact factor: 2.447

10.  Treatment of experimental human breast cancer and lung cancer brain metastases in mice by macitentan, a dual antagonist of endothelin receptors, combined with paclitaxel.

Authors:  Ho Jeong Lee; Masaki Hanibuchi; Sun-Jin Kim; Hyunkyung Yu; Mark Seungwook Kim; Junqin He; Robert R Langley; François Lehembre; Urs Regenass; Isaiah J Fidler
Journal:  Neuro Oncol       Date:  2016-04       Impact factor: 12.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.